A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
Summary
- Eligibility
- for people ages 12 years and up (full criteria)
- Location
- at Los Angeles, California and other locations
- Dates
- study startedstudy ends around
- Principal Investigator
- by Noah C. Federman, MD
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCLA
- Noah C. Federman, MD
Dr. Noah Federman is the Director of the Pediatric Bone and Soft Tissue Sarcoma Program at UCLA, part of the UCLA Sarcoma Program and UCLA's Jonsson Comprehensive Cancer Center. Dr. Federman specializes in treating children, adolescents and young adults with these aggressive cancers.
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Novo Nordisk A/S
- Links
- Sign up for this study
- ID
- NCT06612268
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 408 study participants
- Last Updated